Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future

scientific article

Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID26503994

P50authorJohannes HaybaeckQ56955634
Tobias KiesslichQ73178545
P2093author name stringMarc D Bullock
Martin Pichler
Armin Gerger
Michael Stotz
P433issue11
P407language of work or nameEnglishQ1860
P921main subjecthepatocellular carcinomaQ1148337
P304page(s)5737-5744
P577publication date2015-11-01
P1433published inAnticancer ResearchQ326290
P1476titleMolecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future
P478volume35

Reverse relations

cites work (P2860)
Q4715941820(S)-Protopanaxadiol enhances angiogenesis via HIF-1α-mediated VEGF secretion by activating p70S6 kinase and benefits wound healing in genetically diabetic mice
Q26740313Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis
Q47193804Clinical role and biological function of CDK5 in hepatocellular carcinoma: A study based on immunohistochemistry, RNA-seq and in vitro investigation
Q41471395Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
Q36879787Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
Q42679004Downregulation of miR‑136‑5p in hepatocellular carcinoma and its clinicopathological significance
Q59135320Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma
Q61813759Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients
Q52694975Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma.
Q28078111HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists
Q92876631Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
Q41632307Inhibition of mTORC1 signaling sensitizes hepatocellular carcinoma cells to glycolytic stress
Q47156516Jujube leaf green tea extracts inhibits hepatocellular carcinoma cells by activating AMPK.
Q92134426KIF15 Promotes Proliferation and Growth of Hepatocellular Carcinoma
Q58806320LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21
Q91828636LncRNA NEAT1 Promotes Proliferation, Migration And Invasion Via Regulating miR-296-5p/CNN2 Axis In Hepatocellular Carcinoma Cells
Q93193698Macrophage-associated lncRNA ELMO1-AS1: a novel therapeutic target and prognostic biomarker for hepatocellular carcinoma
Q55646454Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.
Q37360440Multifunctional SPIO/DOX-loaded A54 Homing Peptide Functionalized Dextran-g-PLGA Micelles for Tumor Therapy and MR Imaging
Q58758006Role of canonical Hedgehog signaling pathway in liver
Q54251317SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression.
Q47094928SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types.
Q57301434Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
Q33592056The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data

Search more.